Option Care Health, Inc. $OPCH Shares Acquired by Advantage Alpha Capital Partners LP

Key Points

• Advantage Alpha Capital Partners LP has increased its stake in Option Care Health by 78.7%, making the stock its fourth largest position.
• Option Care Health reported a 15.4% increase in quarterly revenue year-over-year, with earnings per share beating analyst estimates.
• Multiple brokerages have updated their target prices for Option Care Health, with JMP Securities increasing it to $38.00 and UBS Group upgrading it to a "buy" rating.

Advantage Alpha Capital Partners LP boosted its position in Option Care Health, Inc. (NASDAQ:OPCH - Free Report) by 78.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 214,619 shares of the company's stock after buying an additional 94,528 shares during the quarter. Option Care Health accounts for approximately 1.8% of Advantage Alpha Capital Partners LP's holdings, making the stock its 4th biggest holding. Advantage Alpha Capital Partners LP owned about 0.13% of Option Care Health worth $7,501,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in OPCH. Brooklyn Investment Group lifted its holdings in Option Care Health by 186.6% in the 1st quarter. Brooklyn Investment Group now owns 1,198 shares of the company's stock worth $42,000 after buying an additional 780 shares in the last quarter. Public Employees Retirement System of Ohio lifted its holdings in Option Care Health by 21.6% in the 4th quarter. Public Employees Retirement System of Ohio now owns 1,870 shares of the company's stock worth $43,000 after buying an additional 332 shares in the last quarter. Johnson Financial Group Inc. acquired a new position in Option Care Health in the 4th quarter worth $47,000. Bessemer Group Inc. lifted its holdings in Option Care Health by 62.3% in the 1st quarter. Bessemer Group Inc. now owns 1,560 shares of the company's stock worth $54,000 after buying an additional 599 shares in the last quarter. Finally, Wealthquest Corp acquired a new position in Option Care Health in the 1st quarter worth $66,000. Institutional investors and hedge funds own 98.05% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. JMP Securities boosted their price objective on shares of Option Care Health from $36.00 to $38.00 and gave the stock a "market outperform" rating in a report on Thursday, July 31st. Barrington Research restated an "outperform" rating and issued a $38.00 target price on shares of Option Care Health in a research note on Thursday, July 10th. UBS Group upgraded shares of Option Care Health from a "neutral" rating to a "buy" rating and upped their target price for the company from $38.00 to $40.00 in a research note on Wednesday, April 30th. Finally, Citigroup restated an "outperform" rating on shares of Option Care Health in a research note on Thursday, July 31st. Eight investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $35.75.

Insider Buying and Selling

In related news, Director Harry M. Jansen Kraemer, Jr. purchased 36,000 shares of Option Care Health stock in a transaction dated Wednesday, August 20th. The stock was bought at an average cost of $27.15 per share, with a total value of $977,400.00. Following the purchase, the director owned 375,390 shares in the company, valued at approximately $10,191,838.50. The trade was a 10.61% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Timothy P. Sullivan purchased 20,000 shares of Option Care Health stock in a transaction dated Thursday, August 21st. The stock was bought at an average cost of $27.51 per share, with a total value of $550,200.00. Following the completion of the purchase, the director owned 49,229 shares in the company, valued at approximately $1,354,289.79. This trade represents a 68.43% increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 0.64% of the company's stock.

Option Care Health Stock Performance

Shares of NASDAQ:OPCH traded up $0.90 during trading on Friday, reaching $28.74. 2,369,675 shares of the company's stock traded hands, compared to its average volume of 1,997,394. Option Care Health, Inc. has a 12 month low of $21.39 and a 12 month high of $35.53. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.52 and a quick ratio of 1.00. The stock has a market capitalization of $4.66 billion, a P/E ratio of 22.99, a price-to-earnings-growth ratio of 1.75 and a beta of 0.79. The company has a 50 day moving average of $29.92 and a 200-day moving average of $31.76.

Option Care Health (NASDAQ:OPCH - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.40 by $0.01. Option Care Health had a net margin of 3.93% and a return on equity of 17.53%. The firm had revenue of $1.42 billion during the quarter, compared to analysts' expectations of $1.35 billion. During the same quarter in the prior year, the firm earned $0.30 EPS. Option Care Health's quarterly revenue was up 15.4% on a year-over-year basis. Option Care Health has set its FY 2025 guidance at 1.650-1.720 EPS. On average, equities analysts expect that Option Care Health, Inc. will post 1.22 EPS for the current year.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.